knowledge -WSS

knowledge

author：knowledge 2025-09-30 18:21:00 - browse：99288

Boxes of Wegovy — pharma coverage from STAT — Carsten Snejbjerg/Bloomberg

LONDON — The investment arm of Novo Nordisk’s parent foundation is buying drug manufacturer Catalent in a $16.5 billion deal, an acquisition that will give Novo additional sites as it builds up production of its booming obesity and diabetes drugs.

Under the deal, Novo Holdings is purchasing Catalent, a major contract development and manufacturing company with more than 50 sites globally. In turn, Novo Nordisk is buying three of Catalent’s fill-finish sites from the investment group for $11 billion. Novo Holdings manages the assets of the Novo Nordisk Foundation, which has a controlling stake in the pharmaceutical company.

Catalent has been involved in the production of Novo’s obesity treatment Wegovy. With the agreement, Novo will pick up sites that focus on filling drugs in Italy, Brussels, and Bloomington, Ind. All have already been doing work for Novo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Smaller biotechs seek to piggyback on weight loss drug boom

Wikipedia

WSS

Results on Novartis prostate cancer therapy could expand its use

Questions loom on AstraZeneca cancer drug as safety concerns ebb

UnitedHealth, Optum discontinue NaviHealth name

How Robert F. Kennedy Jr. distorted vaccine science

Readout LOUD podcast: Live from the 2023 STAT Summit

STAT Summit: Ending the crisis of Black deaths in the U.S.

focus

knowledge

explore

After affirmative action ruling, medical educators look to 'holistic review'

Roche acquires Telavant from Roivant, adding experimental IBD treatment

23andMe had bad news about my health. I wish a person had delivered it

AstraZeneca lung cancer study comes in below expectations

Medical records are filled with copy

Merck, Daiichi strike cancer drug pact worth up to $22 billion

Medical leaders decry Supreme Court decision on affirmative action

STAT Summit: Meghan O’Rourke on making chronic illness visible

The high cost of giving birth even with insurance

Prescription digital therapeutics are key to pharma’s future

Wikipedia

J&J lung cancer data amount to new salvo against AstraZeneca

STAT Summit: Meghan O’Rourke on making chronic illness visible

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

Roche drug slashes death risk in early

Hubble vs. James Webb telescope images: See the difference

STAT Readout: Friday, Oct. 20 biotech updates

Wikipedia

hotspot

hotspot

Wikipedia